HUP0400114A2 - Daganatellenes N-benzoil-benzolszulfonamid-származékok és az ezeket tartalmazó gyógyászati készítmények - Google Patents

Daganatellenes N-benzoil-benzolszulfonamid-származékok és az ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0400114A2
HUP0400114A2 HU0400114A HUP0400114A HUP0400114A2 HU P0400114 A2 HUP0400114 A2 HU P0400114A2 HU 0400114 A HU0400114 A HU 0400114A HU P0400114 A HUP0400114 A HU P0400114A HU P0400114 A2 HUP0400114 A2 HU P0400114A2
Authority
HU
Hungary
Prior art keywords
alkyl
atom
compounds
alkoxy
phenyl
Prior art date
Application number
HU0400114A
Other languages
English (en)
Inventor
Thomas Hughes Corbett
Cora Sue Grossman
Karen Lynn Lobb
Chuan Shih
Philip Arthur Hipskind
Ho-Shen Lin
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0400114A2 publication Critical patent/HUP0400114A2/hu
Publication of HUP0400114A3 publication Critical patent/HUP0400114A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • C07D213/34Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek vagy ezekgyógyászatilag megfelelő bázisaddíciós sói képezik; a találmánytárgyához tartoznak a (II) általános képletű vegyületeket vagy ezekgyógyászatilag megfelelő bázisaddíciós sóit tartalmazó gyógyászatikészítmények, valamint a (II) általános képletű vegyületek alkalmazásadaganatos betegségek kezelésére adható gyógyászati készítményekelőállítására. A találmány szerinti vegyületek és ezeket tartalmazógyógyászati készítmények eredményesen adhatók rákos megbetegedésekkezelésére, elsősorban bélrák és végbélrák kezelésére. Az (I) és (II)általános képletben a szubsztituensek jelentése például: R1 jelentésehidrogénatom, halogénatom, alkil-, alkoxi-, alkil-tio-, -CF3, -OCF3, -SCF3, alkoxi-karbonil-, nitro-, azido-, -O(SO2)CH3, -N(CH3)2,hidroxil-, fend-, szubsztituált fenil-, piridil-, tienil-, furil-,kinolil- vagy triazolilcsoport, R2 jelentése hidrogénatom,halogénatom, ciano-, -CF3, alkil-, alkoxi-karbonil-, alkoxi-, fenil-vagy kinolilcsoport, R3 jelentése hidrogénatom, halogénatom, alkil-, -CF3 vagy nitrocsoport, R4 jelentése halogénatom, alkilcsoport vagy -CF3, azzal a feltétellel, hogy R3 és R4 közül csak az egyik jelenthetalkilcsoportot Az (I) általános képletű vegyületeknél még két továbbimegkötés is fennáll, így: a) amennyiben R3 és R4 jelentése egyarántklóratom és R2 jelentése hidrogénatom, úgy Rl jelentése brómatom,jódatom, alkoxi-, alkil-tio-, -CF3, -OCF3, nitro-, azido-, -O(SO2)-CH3, -N(CH3)2, hidroxil-, fenil-, szubsztituált fenil-, piridil-,tienil-, furil- vagy triazolilcsoport; b) amennyiben R3 és R4jelentése egyaránt klóratom és R1 jelentése hidrogénatom, úgy R2jelentése brómatom, fluoratom, -CF3, alkil-, alkoxi-, fenil- vagykinolilcsoport. Ó
HU0400114A 2001-06-06 2002-05-24 N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them HUP0400114A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06
PCT/US2002/015142 WO2002098848A1 (en) 2001-06-06 2002-05-24 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents

Publications (2)

Publication Number Publication Date
HUP0400114A2 true HUP0400114A2 (hu) 2005-04-28
HUP0400114A3 HUP0400114A3 (en) 2007-05-02

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400114A HUP0400114A3 (en) 2001-06-06 2002-05-24 N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them

Country Status (36)

Country Link
US (1) US7183320B2 (hu)
EP (1) EP1401806B1 (hu)
JP (1) JP4167173B2 (hu)
KR (1) KR100880760B1 (hu)
CN (1) CN100475787C (hu)
AR (1) AR036079A1 (hu)
AT (1) ATE335722T1 (hu)
AU (1) AU2002259204B2 (hu)
BR (1) BR0210078A (hu)
CA (1) CA2446719A1 (hu)
CR (1) CR7182A (hu)
CY (1) CY1105386T1 (hu)
CZ (1) CZ20033296A3 (hu)
DE (1) DE60213810T2 (hu)
DK (1) DK1401806T3 (hu)
EA (1) EA005810B1 (hu)
EC (1) ECSP034874A (hu)
EG (1) EG24356A (hu)
ES (1) ES2269688T3 (hu)
HK (1) HK1064360A1 (hu)
HR (1) HRP20031000A2 (hu)
HU (1) HUP0400114A3 (hu)
IL (1) IL158985A0 (hu)
MX (1) MXPA03011197A (hu)
MY (1) MY136855A (hu)
NO (1) NO20035366L (hu)
NZ (1) NZ529098A (hu)
PE (1) PE20030199A1 (hu)
PL (1) PL367188A1 (hu)
PT (1) PT1401806E (hu)
SK (1) SK14642003A3 (hu)
SV (1) SV2003001076A (hu)
TW (1) TWI266761B (hu)
UA (1) UA74889C2 (hu)
WO (1) WO2002098848A1 (hu)
ZA (1) ZA200308644B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316984T2 (de) * 2002-11-22 2008-07-17 Eli Lilly And Co., Indianapolis Benzoylsulfonamide als antitumor-mittel
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
ATE542796T1 (de) * 2004-05-26 2012-02-15 Abbott Lab N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
EP1797877A4 (en) * 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
KR20070108270A (ko) 2005-02-28 2007-11-08 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 신규 병용
JPWO2006090928A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の血管新生阻害物質との新規併用
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
CA2606147C (en) 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
WO2008030836A2 (en) 2006-09-05 2008-03-13 Abbott Laboratories Bcl inhibitors treating platelet excess
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101675033A (zh) 2007-05-16 2010-03-17 霍夫曼-拉罗奇有限公司 芳基吡啶基磺酰胺衍生物,它们的制备和作为药剂的应用
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2511264B1 (en) * 2009-01-19 2015-03-11 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2759182C (en) 2009-05-26 2016-06-07 Abbott Laboratories (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RS54388B1 (en) * 2010-03-25 2016-04-28 Abbvie Inc. APOPTOSIS INDICATORS TO CANCER CANCER AND IMMUNE AND AUTOMATIC DISEASES
JP6068352B2 (ja) 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
ES2644230T3 (es) 2010-11-23 2017-11-28 Abbvie Inc. Sales y formas cristalinas de un agente inductor de apoptosis
EP2642999B1 (en) 2010-11-23 2016-09-28 AbbVie Bahamas Ltd. Methods of treatment using selective bcl-2 inhibitors
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
EP3259250A1 (en) 2015-02-13 2017-12-27 Oxford Drug Design Limited Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
WO2018237163A1 (en) * 2017-06-23 2018-12-27 Roman Manetsch 5-AMINOLEVULINATE SYNTHASE INHIBITORS AND METHODS OF USE
WO2019133797A1 (en) * 2017-12-29 2019-07-04 Wu, Lester J. Benzenesulfonamide derivatives and method for modulating lipid raft
CN114790149A (zh) * 2021-01-26 2022-07-26 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
DE69625622T2 (de) * 1995-10-25 2003-08-14 Senju Pharma Co Angiogenese Inhibitoren
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2879300A (en) * 1999-02-12 2000-08-29 Cellpath, Inc. Methods for anti-tumor therapy
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis

Also Published As

Publication number Publication date
ES2269688T3 (es) 2007-04-01
KR20040007656A (ko) 2004-01-24
UA74889C2 (en) 2006-02-15
PL367188A1 (en) 2005-02-21
BR0210078A (pt) 2004-06-22
SK14642003A3 (sk) 2004-12-01
CN1514824A (zh) 2004-07-21
DK1401806T3 (da) 2006-11-27
IL158985A0 (en) 2004-05-12
CR7182A (es) 2004-06-08
EG24356A (en) 2009-03-04
DE60213810D1 (de) 2006-09-21
EA005810B1 (ru) 2005-06-30
EP1401806A1 (en) 2004-03-31
HUP0400114A3 (en) 2007-05-02
PE20030199A1 (es) 2003-03-12
NO20035366D0 (no) 2003-12-02
JP4167173B2 (ja) 2008-10-15
EA200400006A1 (ru) 2004-06-24
US7183320B2 (en) 2007-02-27
SV2003001076A (es) 2003-07-29
PT1401806E (pt) 2006-11-30
CA2446719A1 (en) 2002-12-12
CZ20033296A3 (cs) 2004-04-14
TWI266761B (en) 2006-11-21
NZ529098A (en) 2005-08-26
NO20035366L (no) 2004-02-06
AR036079A1 (es) 2004-08-11
MY136855A (en) 2008-11-28
JP2004530709A (ja) 2004-10-07
MXPA03011197A (es) 2004-02-26
KR100880760B1 (ko) 2009-02-02
US20040157741A1 (en) 2004-08-12
DE60213810T2 (de) 2007-02-01
HRP20031000A2 (en) 2004-04-30
HK1064360A1 (en) 2005-01-28
CY1105386T1 (el) 2010-04-28
CN100475787C (zh) 2009-04-08
AU2002259204B2 (en) 2008-01-17
ZA200308644B (en) 2005-02-07
WO2002098848A1 (en) 2002-12-12
ECSP034874A (es) 2004-01-28
ATE335722T1 (de) 2006-09-15
EP1401806B1 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
HUP0400114A2 (hu) Daganatellenes N-benzoil-benzolszulfonamid-származékok és az ezeket tartalmazó gyógyászati készítmények
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
HUP0101434A2 (hu) Szulfonamidcsoportot tartalmazó indolszármazékok, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
HUP0303538A2 (hu) Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
CY1107974T1 (el) Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1
MA27040A1 (fr) Nucleosides substitues en 4'
CY1112232T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0400704A2 (hu) Heterociklusos éterrel szubsztituált imidazokinolinok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EA200600892A1 (ru) Новые хинолиновые производные
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
HUP0103884A2 (hu) Arilszulfonanilidkarbamid-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
AR054863A1 (es) DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CY1110284T1 (el) Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο
HUP0203422A2 (hu) Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MEP21308A (en) Ryl alkyl carbamate derivatives production and use thereof in therapy
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
DE60206505D1 (de) Substituierte benzopyran derivate gegen arrhythmie
HUP0004020A2 (hu) Triciklusos triazolo-benzazepin-származékok, eljárás a vegyületek előállítására és alkalmazásuk antiallergiás szerként
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees